Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma

Inclusion Criteria

• •1. Age: 18 \~75 years old.
• •2. Patients who are diagnosed pathologically with relapsed/metastatic renal cell carcinoma have a disease progression on standard of care.
• •3. Performance status: Eastern Cooperative Oncology Group performance status ≦2.
• •4. Life expectancy more than 3 months.
• •5. Patients have adequate organ function, accord with following criteria: A. blood routine: Hemoglobin≥90g/L, absolute neutrophil count≥1.5×109/L, platelet count ≥ 80×109/L; B. Biochemical tests: total bilirubin is less than 1.5 times upper limit of normal, alanine aminotransferase and aspartate aminotransferase are less than 2.5 times upper limit of normal; C. creatinine less than 1.25 times upper limit of normal.
• •6. Patients agree to use adequate contraception in the period of trial and need negative pregnancy test in childbearing potential women.
• •7. Patients agree to receive treatment with epigenetic drugs.
• •8. Participant sign an institutional review board-approved, protocol-specific informed consent form in accordance with institutional guidelines.
• •Exclude criteria:
• •1. Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods.
• •2. Organs failure.
• •3. ECOG \>2.
• •4. Serious/active infection.
• •5. Autoimmune disorders or immunodeficiency diseases.
• •6. Patients with allergic constitution, or other disease need take drugs of immunosuppressant or corticosteroids.
• •7. Uncontrolled hypertension.
• •8. Myocardial ischemia (more than grade II ) or myocardial infarction or uncontrolled arrhythmia.
• •9. Cardiac insufficiency of grade III to IV according to NYHA criteria, or left ventricular ejection fraction (LVEF) \<50%.
• •10. Coagulation disorders, tendency of haemorrhage, undergoing thrombolytic or anticoagulant therapy.
• •11. Unhealed wounds, or fractures.
• •12. With a history of psychotropic drug abuse or mental disorders.
• •13. Prior systemic therapies with any antitumor agents within 4 weeks.
• •14. With other uncurable cancers simultaneously.